This site uses cookies to improve your experience and to provide services and advertising. By continuing to browse, you agree to the use of cookies described in our Cookies Policy. You may change your settings at any time but this may impact on the functionality of the site. To learn more see our Cookies Policy.
OK
Dublin: 12 °C Thursday 24 May, 2018
Advertisement

The government will fund life-prolonging treatment for a terminal cancer patient

The drug is believed to cost between €65,000 and €85,000 per patient.

Margaret Ready
Margaret Ready

THE HSE HAVE come to an agreement with a drug company to fund a life-prolonging drug treatment for a terminally-ill cancer patient.

Margaret Ready had previously begged the government to pay for a chemotherapy drug called TDM1 (Kadcyla) which she claims she has been told will prolong her life.

The drug is believed to cost between €65,000 and €85,000 per patient.

Ready has launched a petition asking for signatures of support. The 59-year-old told the Irish Daily Mail that the drug is her final hope.

Today, a Facebook page linked with her campaign announced that the HSE and drug company Roche had come to an agreement on the drug.

A post read:

Margaret received wonderful news the HSE and the drug company Roche have come to an agreement over the drug that Margaret needs and the HSE are going to fund TDM-1 (Kadcyla) there is an article in today’s Daily Mail. On behalf of Margaret and myself we would like to thank everyone for your help and support , to all that went out and got petitions signed and to all that signed both the written petition and the online petition, to all that liked and shared our appeal page we thank you for your support and kind words.

Speaking to the Daily Mail today, Margaret said that she was “over the moon”.

“It means so much just to get the chance to prolong my life with this drug. It is unbelievable.”

Read: Terminal cancer patient pleads with government to pay for drug that could prolong her life

  • Share on Facebook
  • Email this article
  •  

Read next:

COMMENTS (16)

This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
write a comment

Leave a commentcancel